Loading...
Loading...
SLS| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 7,146.0K |
| Operating I/L | -7,146.0K |
| Other Income/Expense | 124.0K |
| Interest Income | 111.0K |
| Pretax | -7,022.0K |
| Income Tax Expense | -235.0K |
| Net Income/Loss | -6,787.0K |
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. Its lead product candidate, galinpepimut-S (GPS), is in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 trials for ovarian cancer. The company also develops nelipepimut-S, targeting human epidermal growth factor receptor 2, in Phase 2b trials for early-stage breast cancer. SELLAS has a strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with pembrolizumab in Phase 1/2 trials for multiple cancer indications. The company generates revenue through the development and potential commercialization of its cancer immunotherapeutic agents.
